Ultragenyx Q2 Revenue Hits Record $214M, Gene Therapy Decisions Loom

मुख्य तथ्य

Q2 2026 revenue: $214 million (record)
Crysvita revenue: $156 million
Net loss: $92 million ($0.90 per share)
Cash and securities (June 30): $436 million
PDUFA date for DTX-401: Aug. 23
PDUFA date for UX-111: Sept. 19

पृष्ठभूमि

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Founded in 2010 and headquartered in Novato, California, the company has built expertise in protein replacement therapies, small molecules, and gene therapy approaches.

Its commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII, and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

वर्तमान स्थिति

Ultragenyx reported record second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio. CEO Emil Kakkis said the quarter marked the company's highest quarterly revenue to date and supported its reaffirmed full-year revenue guidance.

CFO Howard Horn detailed that Crysvita generated $156 million, including $94 million in North America, $54 million in Latin America and Turkey, and $8 million in Europe. DOJOLVI contributed $27 million, Evkeeza generated $21 million (up 50% from Q2 2025), and MEPSEVII revenue was $10 million.

The company posted a net loss of $92 million, or $0.90 per share, for the quarter. As of June 30, it had $436 million in cash equivalents and marketable securities. Net cash used in operations was $97 million, significantly lower than in the first quarter.

Q2 2026 Revenue by Product
Product	Revenue ($ million)
Crysvita	156
DOJOLVI	27
Evkeeza	21
MEPSEVII	10

Revenue figures as reported by Ultragenyx for Q2 2026.

प्रभाव

Ultragenyx is approaching key regulatory decisions for gene therapies DTX-401 and UX-111, with FDA action expected by Aug. 23 and Sept. 19, respectively. These decisions could affect patients with glycogen storage disease type Ia and Sanfilippo syndrome type A, as well as the company's future revenue streams.

The company has advanced launch preparations, including treatment-center readiness and more than 200 payer engagements. Approximately 75% of institutions and healthcare providers involved with the potential gene therapies also serve DOJOLVI and MEPSEVII patients, which may facilitate commercial rollout.

In Latin America, about 50 patients began commercial Crysvita therapy during the quarter, bringing the regional total to 1,000 patients. More than 100 patients in Turkey are receiving Crysvita through a named-patient program. DOJOLVI had about 675 patients on reimbursed treatment in North America and about 300 in Europe through named-patient or early-access programs.

भविष्य का दृष्टिकोण

Scenario analysis: The possibilities below are not certain predictions.

Ultragenyx sees a potential path to profitability in 2027 through continued product growth, potential contributions from upcoming launches, expense discipline, and possible monetization of priority review vouchers. The company expects 2026 combined R&D and SG&A spending to be flat to down low single digits from 2025, with 2027 spending expected to decline by at least 15%.

Phase III Angelman syndrome data for GTX-102 (apazunersen) are expected in September or October. The study's statistical alpha is split between the Bayley-4 cognitive raw score (80%) and the Multi-Domain Responder Index (20%). A statistically successful study would require a Bayley endpoint p-value of 0.04 or less, or an MDRI p-value of 0.01 or less.

The regulatory path for setrusumab (UX143) for osteogenesis imperfecta remains uncertain after two studies missed their primary fracture-reduction endpoints. The U.K.'s MHRA indicated a new randomized study may be required, while the FDA has been open to discussing alternative fracture analyses. Further discussions are needed to determine additional clinical data required for a potential biologics license application.

Source: yahoo.com

AMRIT EXPLAINER